Next Article in Journal
Release Kinetics of Papaverine Hydrochloride from Tablets with Different Excipients
Previous Article in Journal
Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Preparation, In Vitro Characterization, and In Vivo Pharmacokinetic Evaluation of Respirable Porous Microparticles Containing Rifampicin

by
Aliasgar KUNDAWALA
1,*,
Vishnu PATEL
2,
Harsha PATEL
1 and
Dhaglaram CHOUDHARY
1
1
Indukaka Ipcowala College of Pharmacy, New Vallabh Vidyanagar, Dist. Anand (Gujarat) – 388121, India
2
A. R. College of Pharmacy and G H Patel Institute of pharmacy, Vallabh Vidyanagar, Dist. Anand (Gujarat) – 388120, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2014, 82(3), 665-682; https://doi.org/10.3797/scipharm.1307-03
Submission received: 5 July 2013 / Accepted: 23 July 2014 / Published: 23 July 2014

Abstract

This study aimed to prepare and evaluate rifampicin microparticles for the lung delivery of rifampicin as respirable powder. The microparticles were prepared using chitosan by the spray-drying method and evaluated for aerodynamic properties and pulmonary drug absorption. To control the drug release, tripoly-phosphate in different concentrations 0.6, 0.9, 1.2, and 1.5 was employed to get a sustained drug release profile. The microparticles were evaluated for drug loading, % entrapment efficiency, tapped density, morphological characteristics, and in vitro drug release studies. Aerosol properties were determined using the Andersen cascade impactor. Porous microparticles with particle sizes (d0.5) less than 10 μm were obtained. The entrapment of rifampicin in microparticles was up to 72%. In vitro drug release suggested that the crosslinked microparticles showed sustained release for more than 12 hrs. The drug release rate was found to be decreased as the TPP concentration was increased. The microparticles showed a fine particle fraction in the range of 55–63% with mass median aerodynamic diameter (MMAD) values below 3 μm. The in vivo pulmonary absorption of the chitosan microparticles suggested a sustained drug release profile up to 72 hrs with an elimination rate of 0.010 per hr. The studies revealed that the spray-dried porous microparticles have suitable properties to be used as respirable powder in rifampicin delivery to the lungs.
Keywords: Microparticles; Chitosan; Inhalation; Sustained release Microparticles; Chitosan; Inhalation; Sustained release

Share and Cite

MDPI and ACS Style

KUNDAWALA, A.; PATEL, V.; PATEL, H.; CHOUDHARY, D. Preparation, In Vitro Characterization, and In Vivo Pharmacokinetic Evaluation of Respirable Porous Microparticles Containing Rifampicin. Sci. Pharm. 2014, 82, 665-682. https://doi.org/10.3797/scipharm.1307-03

AMA Style

KUNDAWALA A, PATEL V, PATEL H, CHOUDHARY D. Preparation, In Vitro Characterization, and In Vivo Pharmacokinetic Evaluation of Respirable Porous Microparticles Containing Rifampicin. Scientia Pharmaceutica. 2014; 82(3):665-682. https://doi.org/10.3797/scipharm.1307-03

Chicago/Turabian Style

KUNDAWALA, Aliasgar, Vishnu PATEL, Harsha PATEL, and Dhaglaram CHOUDHARY. 2014. "Preparation, In Vitro Characterization, and In Vivo Pharmacokinetic Evaluation of Respirable Porous Microparticles Containing Rifampicin" Scientia Pharmaceutica 82, no. 3: 665-682. https://doi.org/10.3797/scipharm.1307-03

APA Style

KUNDAWALA, A., PATEL, V., PATEL, H., & CHOUDHARY, D. (2014). Preparation, In Vitro Characterization, and In Vivo Pharmacokinetic Evaluation of Respirable Porous Microparticles Containing Rifampicin. Scientia Pharmaceutica, 82(3), 665-682. https://doi.org/10.3797/scipharm.1307-03

Article Metrics

Back to TopTop